載入...
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
BACKGROUND: Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy. METHODS: We conducted a single-arm, phase II study of patients with triple negative (TN...
Na minha lista:
| 發表在: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057426/ https://ncbi.nlm.nih.gov/pubmed/32060053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000173 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|